BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory and others had found previously, inoculation was able to confer resistance to arguments that were not specifically mentioned in the inoculation message. Compton and Ivanov (2013) offer a comprehensive review of political inoculation scholarship and outline new directions for future work. Sample studies include: Pfau and some of his colleagues examined inoculation through the use of direct mail during the 1988 presidential campaign. The researchers were specifically interested in comparing inoculation and post hoc refutation. Post hoc refutation is another form of building resistance to arguments, however, instead of building resistance prior to future arguments, like inoculation, it attempts to